Leronlimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CCR5 |
| Clinical data | |
| Other names | PRO 140 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| NIAID ChemDB | |
| (verify) | |
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer[1] and HIV infection.[2]
The United States Food and Drug Administration has designated PRO 140 for fast-track approval.[3]
It was investigated as a treatment for COVID-19 but found to be ineffective for that purpose.
- ^ Clinical trial number NCT03838367 for "Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC " at ClinicalTrials.gov
- ^ "CytoDyn Announces Acquisition of PRO 140". CytoDyn Inc. October 17, 2012. Archived from the original on September 25, 2013. Retrieved December 18, 2012.
- ^ Lawler B (2 May 2007). "Progenics' Intriguing Study Results". The Motley Fool.